KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Teva Pharmaceutical Industries (TEVA) EBIAT (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed EBIAT for 10 consecutive years, with $470.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIAT rose 282.88% year-over-year to $470.0 million, compared with a TTM value of $1.6 billion through Dec 2025, up 182.59%, and an annual FY2025 reading of $1.4 billion, up 171.98% over the prior year.
  • EBIAT was $470.0 million for Q4 2025 at Teva Pharmaceutical Industries, down from $646.0 million in the prior quarter.
  • Across five years, EBIAT topped out at $646.0 million in Q3 2025 and bottomed at -$1.2 billion in Q4 2022.
  • Average EBIAT over 5 years is -$143.0 million, with a median of -$44.0 million recorded in 2021.
  • The sharpest move saw EBIAT plummeted 1236.9% in 2022, then skyrocketed 282.88% in 2025.
  • Year by year, EBIAT stood at -$151.0 million in 2021, then crashed by 708.61% to -$1.2 billion in 2022, then skyrocketed by 135.14% to $429.0 million in 2023, then crashed by 159.91% to -$257.0 million in 2024, then surged by 282.88% to $470.0 million in 2025.
  • Business Quant data shows EBIAT for TEVA at $470.0 million in Q4 2025, $646.0 million in Q3 2025, and $282.0 million in Q2 2025.